Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ulocladium atrum keratitis.

P R Badenoch1, C L Halliday, D H Ellis

  • 1Department of Ophthalmology, Flinders Medical Centre and Flinders University of South Australia, Bedford Park, South Australia 5042, Australia. p.badenoch@flinders.edu.au

Journal of Clinical Microbiology
|March 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The challenges of <i>Candidozyma auris</i>: updates on the laboratory investigation, infection prevention and management.

Future microbiology·2026
Same author

Mucormycosis in Australia: contemporary epidemiology and outcomes.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same author

Clinical utility of panfungal polymerase chain reaction for the diagnosis of invasive fungal disease: a single center experience.

Medical mycology·2015
Same author

Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer?

Pathology·2015
Same author

A sociogram for the cranes of the world.

Behavioural processes·2014
Same author

Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.

The Journal of antimicrobial chemotherapy·2014
Same journal

Ebola laboratory preparedness at frontline hospitals: can we or can't we?

Journal of clinical microbiology·2026
Same journal

Reporting macrolide-resistant <i>Mycoplasma pneumoniae</i>: a diagnostic obligation?

Journal of clinical microbiology·2026
Same journal

Diagnostic value of HHV-6A/B genotyping in immunocompromised adults.

Journal of clinical microbiology·2026
Same journal

Multicenter performance evaluation of the Simplexa <i>C. auris</i> Direct assay for the detection of <i>Candida auris</i> colonization in bilateral axilla/groin swabs.

Journal of clinical microbiology·2026
Same journal

Comparison of blood culture contamination rates with standard practice versus two blood diversion devices at a single institution.

Journal of clinical microbiology·2026
Same journal

Risk assessment and mitigation of hepatitis C virus RNA carryover contamination in a reflex testing algorithm.

Journal of clinical microbiology·2026
See all related articles

A rare fungal infection, Ulocladium atrum keratitis, was successfully treated in a 43-year-old man using natamycin and fluconazole drops. This case highlights a previously unreported human pathogen, Ulocladium atrum, a dematiaceous hyphomycete.

Area of Science:

  • Ophthalmology
  • Mycology
  • Infectious Diseases

Background:

  • Ulocladium atrum is a dematiaceous hyphomycete not previously documented as a human pathogen.
  • Fungal keratitis can lead to significant vision impairment if not promptly diagnosed and treated.

Observation:

  • A 43-year-old male presented with keratitis of unknown etiology.
  • No predisposing factors for infection were identified in the patient's history.

Findings:

  • Morphological and rRNA gene sequence analyses confirmed the causative agent as Ulocladium atrum.
  • The patient's keratitis resolved following treatment with topical natamycin and fluconazole.

Implications:

  • This case establishes Ulocladium atrum as a novel agent capable of causing human keratitis.

Related Experiment Videos

  • The successful treatment underscores the efficacy of standard antifungal agents against this emerging pathogen.
  • Further research is warranted to understand the epidemiology and potential risk factors associated with Ulocladium atrum infections.